Holen Sie sich die Stockscreener-App
157.24
1.14%
1.77
Schlusskurs vom Vortag:
$155.47
Offen:
$152.95
24-Stunden-Volumen:
162.22K
Relative Volume:
0.66
Marktkapitalisierung:
$2.27B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-49.30M
KGV:
-37.72
EPS:
-4.1688
Netto-Cashflow:
$-29.10M
1W Leistung:
+4.85%
1M Leistung:
+3.45%
6M Leistung:
+16.05%
1J Leistung:
+190.43%
1-Tages-Spanne:
$152.95
$157.45
1-Wochen-Bereich:
$143.47
$157.45
52-Wochen-Spanne:
$52.36
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
157.24 | 2.05B | 1.30M | -49.30M | -29.10M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Mizuho | Outperform |
| 2025-12-05 | Eingeleitet | BTIG Research | Buy |
| 2025-12-04 | Eingeleitet | Craig Hallum | Buy |
| 2025-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
36,259 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Blue Owl Capital Holdings LP - MarketBeat
Palvella Therapeutics COO Kathleen Goin Executes Stock Option Exercises and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock - MarketBeat
Palvella Therapeutics (NASDAQ: PVLA) COO sells 4,302 shares under 10b5-1 plan - Stock Titan
Palvella Therapeutics, Inc (NASDAQ: PVLA) Share Price, PVLA Stock News, PVLA Share Price & Updates - kalkine.ca
Palvella (PVLA) Latest Quarter: EPS Comes in Below Forecast in the Available Record; Share Response: Shares Fall 6.03% for the Current SessionConsensus Forecast Report - vinanet.vn
Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel - Seeking Alpha
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - MarketBeat
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Th - GuruFocus
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst - marketbeat.com
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
High-Risk Warning for Investors in Palvella Therapeutics Securities - The Globe and Mail
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call - Sahm
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - moomoo.com
Palvella Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PVLA) 2026-08-05 - Seeking Alpha
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207 - Moomoo
Palvella details QTORIN progress and Nasdaq uplisting milestones - The Globe and Mail
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ... - finance.yahoo.com
Palvella Therapeutics Q2 Earnings Call Highlights - MarketBeat
Palvella Therapeutics, Inc.Common Stock (PVLA) Stock Price, News, Quote & History - FinancialContent
Earnings call transcript: Palvella shares rise on q2 2026 launch progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS - MarketBeat
PVLA: Positive phase III data, rolling NDA, and strong cash position drive launch readiness and pipeline growth - TradingView
PVLA: QTORIN rapamycin advanced toward FDA approval with strong phase III data, robust cash, and launch readiness - TradingView
Palvella Therapeutics Q2 Net Loss Widens - marketscreener.com
Palvella Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palvella Therapeutics, Inc. (PVLA) Q2 FY2026 earnings call transcript - Yahoo Finance
Palvella Therapeutics Q2 net loss widens on higher expenses - TradingView
PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9M - TradingView
Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss - marketscreener.com
Palvella Therapeutics: Q2 Earnings Snapshot - Barchart.com
Palvella Reports Q2 Net Loss and Advances QTORIN NDA Plans - Quiver Quantitative
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
All eyes on Palvella earnings as rare disease drug nears approval - Investing.com Nigeria
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Chardan Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-Buy - MarketBeat
Palvella Therapeutics Chief Scientific Officer Jeff - GlobeNewswire
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing - The Manila Times
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palvella Therapeutics Inc-Aktie (PVLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer |
Aug 19 '26 |
Sale |
152.21 |
4,302 |
654,791 |
0 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):